ATLANTA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with two lead revolutionary product candidates in late-stage clinical development for reproductive health in addition to innovative diagnostic products constituting a broad portfolio of in-office accessible solutions, today announced that Kathy Lee-Sepsick, founder, president & chief executive officer, will virtually present and also participate in one-on-one investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.
The company presentation will be accessible on-demand, beginning 7:00 AM EDT, Monday, September 11, 2023. To listen to the presentation, register at the link here. This link will remain active for 90 days from the start of the conference and can also be found on the investor portion of Femasys’ website within the Events & Presentations section.
About Femasys
Femasys is a biomedical company focused on meeting significant unmet needs for women worldwide by developing two lead revolutionary product candidates in late-stage clinical development for reproductive health in addition to innovative diagnostic products constituting a broad portfolio of in-office, accessible solutions. Our FemBloc® permanent birth control in pivotal trial is intended to be a safer, less costly option for women by eliminating surgery and implants. Our FemaSeed® localized directional insemination in pivotal trial for infertility (approved in Canada) is intended to offer couples a safer, less costly alternative by eliminating invasive surgical procedures. Complimentary products with approvals to market in the U.S., Canada and other countries outside the U.S, have allowed the Company to optimize its ability to achieve regulatory approvals, and improve operational efficiencies and commercial readiness with its in-house manufacturing capabilities. Learn more at www.femasys.com, or follow us on Twitter, Facebook and LinkedIn.
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
917-741-7792
This email address is being protected from spambots. You need JavaScript enabled to view it.
Femasys Inc.
Investor Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.24 |
| Daily Change: | 0.16 14.81 |
| Daily Volume: | 502,279 |
| Market Cap: | US$28.400M |
March 27, 2025 February 25, 2025 February 11, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
